ABBV-400 in Select Advanced Solid Tumor Indications

What is the Purpose of this Study?

We are doing this study to find out if an experimental drug called ABBV-400 (the study drug) is a safe and effective option for treating various types of solid tumors.

What is the Condition Being Studied?

Advanced Solid Tumors

Who Can Participate in the Study?

Adults ages 18+ who are diagnosed with one of the following types of cancer that is advanced or metastatic:

  • Hepatocellular carcinoma (HCC); OR
  • Biliary tract cancer (BTC); OR
  • Pancreatic ductal adenocarcinoma (PDAC); OR
  • Esophageal squamous cell carcinoma (ESCC); OR
  • Triple-negative breast cancer (TNBC); OR
  • HR-positive and HER2-negative breast cancer (HR+/HER-); OR
  • Head and neck squamous cell carcinoma (HNSCC)

For more information about who can join this study, please contact the study team at gi-oncology-cru@dm.duke.edu or 919-668-1861.

Age Group
Adults

What is Involved?

If you choose to join this study, you will:

  • Get the study drug through an IV once every 3 weeks
  • Have a tumor biopsy done, if necessary
  • Have blood draws
  • Have imaging scans (CT or MRI)

Study Details

Full Title
A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications
Principal Investigator
Headshot of John Strickler
Professor of Medicine
Protocol Number
IRB: PRO00113960
NCT: NCT06084481
Phase
Phase I
ClinicalTrials.gov
Enrollment Status
OPEN TO ACCRUAL